Genetic Factors Affecting HIV Treatment in TB Patients
Author Information
Author(s): Ridolfi Felipe, Amorim Gustavo, Haas David W., Arriaga Maria, Staats Cody, Cordeiro-Santos Marcelo, Kritski Afrânio L., Figueiredo Marina C., Andrade Bruno B., Sterling Timothy R., Rolla Valeria C.
Primary Institution: Vanderbilt University Medical Center
Hypothesis
Can genetic variants of antiretroviral therapy (ART) influence HIV-1 outcomes among TB/HIV patients?
Conclusion
The study found that the proportion of participants achieving virologic suppression was low, and genetic variants affecting ART metabolism were not significantly associated with the likelihood of virologic suppression.
Supporting Evidence
- Among 194 TB/HIV participants included, 32% did not achieve HIV-1 virologic suppression.
- The median time to virologic suppression for efavirenz-based ART was 184 days.
- Overall virologic suppression was suboptimal at 68%.
Takeaway
This study looked at how people's genes might affect their HIV treatment when they also have tuberculosis, and it found that many didn't get better as expected.
Methodology
Participants with TB/HIV were genotyped for specific genetic variants and their virologic suppression was measured after starting ART.
Limitations
Not all participants had viral load measured at the same timepoint, and not all had SNPs available.
Participant Demographics
Most participants were male (77%), with a median age of 35 years, and 57% were ART-naïve.
Statistical Information
P-Value
0.34
Confidence Interval
95% CI 172–203
Statistical Significance
p=0.34
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website